Stay updated with breaking news from Derek Jantz. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The genetic tuning innovator adds pioneering genetic medicine expert and an accomplished biotechnology lawyer to its management team.DURHAM, N.C. & SEATTLE--(BUSINESS WIRE)--Today, leading epigenomic editing company Tune Therapeutics introduced two members to its leadership team: Chief Scientific Officer, Derek Jant...
Oral and Poster Presentations to Highlight Preclinical Research for ARCUS Gene Editing Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS-based ex vivo
Durham-based Precision Biosciences’ genome editing technology has drawn interest – and investment – from another global pharmaceutical giant. This time it’s Novartis.
Precision BioSciences, Inc. (NASDAQ:DTIL – Get Rating) insider Derek Jantz sold 18,849 shares of the firm’s stock in a transaction that occurred on Wednesday, June 8th. The shares were sold at an average price of $2.06, for a total transaction of $38,828.94. Following the sale, the insider now directly owns 4,055,174 shares of the company’s […]